Table of Contents
Introduction
Pompe’s disease, also known as glycogen storage disease type II (GSD II), belongs to a group of diseases called lysosomal storage disorders (LSDs). A lysosome is an organelle (a small structure within a cell with a specific function) wherein digestive enzymes degrade and recycle all kinds of substances. More than 50 different lysosomal storage disorders are present that are known to be caused by the deficiency of one of these digestive enzymes. Acid alpha-glucosidase (GAA) is an enzyme responsible for lysosomal glycogen degradation. A deficiency or dysfunction of GAA leads to glycogen accumulation within the lysosomes, causing cellular malfunction, tissue damage, and organ dysfunction. This is manifested in Pompe’s disease as muscle weakness and muscle wasting. Therefore, Pompe’s disease is not only an LSD but also one of the glycogen storage disorders (GSD) due to abnormalities in glycogen synthesis and breakdown.
What Is Pompes Disease?
Pompe’s disease is a neuromuscular disorder caused by a deficiency of the acid alpha-glucosidase enzyme. The severity of this condition depends on the extent of GAA deficiency; if no or minimal GAA is produced, symptoms may be severe and can be seen in infancy, known as infantile-onset Pompe’s disease (IOPD). When left untreated, it can cause muscle hypotonia and cardio-respiratory failure, causing significant morbidity or mortality during the first year of life.
Late-onset Pompe disease (LOPD) is usually milder but progresses slowly as the patients have a reduced amount of GAA enzyme, and the symptoms occur during adolescence or adulthood. It is unlikely to affect the heart but causes breathing problems and myopathy (muscle weakness), especially in the muscles of the shoulders, arms, diaphragm, hips, and legs. Other symptoms include an ineffective cough, frequent respiratory infections, shortness of breath, muscle pain, hearing problems, difficulty swallowing, an irregular heartbeat, headaches, and inability to do physical exercises.
How Does Pompes Disease Affect the Respiratory System?
The diaphragm muscle (a thin, dome-shaped muscle between the lungs and heart) pushes air in and out of the lungs during respiration. Pompe’s disease, especially of the late-onset type, causes progressive muscle weakness in different body areas, including the diaphragm and the respiratory-related muscles of the neck and abdomen. This leads to diaphragmatic dysfunction, shortness of breath, or breathing that requires increased effort. It is also called air hunger, which can occur while resting or during minimal physical activity. Weakened respiratory muscles reduce the ability to cough and struggle to clear mucus and other particles from the airways, resulting in an increased risk of respiratory infections such as pneumonia (lung infection caused by bacteria, virus, or fungi) or bronchitis (inflammation of the bronchial tubes or airways of the lungs). These can worsen the condition by causing inflammation and increased mucus production, thus potentially leading to life-threatening respiratory insufficiency (difficulty maintaining adequate gas exchange).
What Are the Respiratory Manifestations in Patients With Pompes Disease?
-
Infantile-onset Pompe’s disease manifests within the first year of life and exhibits multiorgan involvement, often requiring ventilator support. It causes cardiomegaly (an abnormal enlargement of the heart), respiratory distress, muscle weakness, and feeding difficulties, necessitating early medical intervention. As the condition progresses, patients develop an impaired cough, and respiratory muscle weakness worsens, compromising airway clearance and increasing the risk of respiratory infections.
-
Pompe’s disease, both IOPD and LOPD, causes diaphragm muscle weakness, macroglossia (large tongue), and upper airway dysfunction. This leads to feeding difficulties due to weakened buccal muscles, dysphagia (swallowing difficulties), and motor neuron involvement, which increases the risk of aspiration pneumonia (lung infection caused by inhaling foreign substances or bacterial-rich fluids). All these complications can contribute to respiratory insufficiency or respiratory failure.
-
Weakness of the diaphragm, lingual, and pharyngeal muscles can also cause nocturnal hypoventilation (slow breathing during sleep), obstructive sleep apnea (recurrent episodes of upper airway collapse during sleep), morning headaches, sleep disruption, and excessive daytime sleepiness, leading to a reduction in the health-related quality of life. However, regular assessment and early intervention can mitigate the impact of these respiratory complications.
How Is Respiratory Function Monitored in Patients With Pompes Disease?
Pompe’s disease affects respiratory and locomotor function over time; however, the correlation is weak, and some patients present with respiratory issues before developing locomotor problems. Therefore, respiratory evaluation is done independently and not based on limb muscle weakness. Healthcare specialists evaluate the respiratory function status in patients with Pompe’s disease periodically (every six months) and annually for stable patients.
The patient's medical history includes a detailed family history, previous respiratory infections, immunization status, hospitalizations for respiratory complications, and the requirement of supplemental oxygen or respiratory support. Respiratory function is monitored, including signs and symptoms, pulse oximetry, pulmonary function tests in the upright and supine positions, evaluation of tongue strength, swallow function, polysomnography studies, and other parameters. Specific tests such as electrocardiography (ECG) and echocardiography are recommended to assess heart function, and chest X-rays help evaluate lung function and the size of the heart. Muscle magnetic resonance imaging (MRI) is beneficial in visualizing the degree of muscle damage.
How Is Respiratory Insufficiency Managed in Patients With Pompes Disease?
Respiratory difficulties brought on by a weakened diaphragm and chest muscles in Pompe’s disease can be managed by various treatment options.
These include:
-
Noninvasive ventilators, such as volume-controlled ventilators, bi-level positive airway pressure ventilators (BiPAP), or continuous positive airway pressure ventilators, facilitate breathing. A cough assist machine helps loosen and remove secretions from the airways.
-
Oxygen therapy is considered if hypoxemia (low oxygen levels in the blood) is observed, which helps increase oxygen levels to meet metabolic demands and maintain vital functions.
-
Enzyme replacement therapy (ERT) was approved in 2006 to treat Pompe’s disease. It involves administering a functional version of the enzyme to improve breathing.
-
Medications such as bronchodilators and inhaled corticosteroids open the airways, reduce inflammation, and improve airflow. Antibiotics are recommended to treat respiratory infections and prevent a decline in pulmonary function.
-
It is important to get annual vaccinations for pneumonia, influenza, and coronavirus to prevent respiratory disorders.
-
Pulmonary rehabilitation programs and breathing exercises help strengthen respiratory muscles, including the diaphragm and intercostal muscles, increasing lung capacity, reducing fatigue, supporting the cardiovascular system, and improving overall endurance.
Conclusion
Pompe’s disease is an autosomal recessive neuromuscular disorder caused by the deficiency of acid-alpha glucosidase (GAA), an enzyme that hydrolyses lysosomal glycogen. Respiratory insufficiency is a prominent feature of Pompe’s disease that significantly impacts the lives of the patients. A multidisciplinary team well-versed in managing this condition must monitor and manage the complications diligently.
Regular pulmonary examinations, vaccinations, ERT, noninvasive ventilation, airway clearance techniques, and medications are vital components of effective respiratory management. Therefore, by implementing these strategies, patients with Pompe’s disease can improve their respiratory health and overall well-being.
